UTI Mid Cap Fund · Regular · Growth
NAV
₹311.3859
as of 13 Nov 2026
Expense Ratio
1.97%
AUM
₹12,421 Cr
Lumpsum returns (CAGR)
- 1Y
- +1.47%
- 3Y
- +10.87%
- 5Y
- +9.61%
- Since Inception
- +16.38%
SIP returns (XIRR)
- 1Y
- +7.19%
- 3Y
- +5.74%
- 5Y
- +10.61%
- Since Inception
- +15.67%
Returns calculated from 22 August 2014 onwards due to a structural change in the scheme on that date. Earlier NAV history is preserved but excluded from multi-year return calculations. Periods spanning this date show —.
What history actually did — last 10 years (Nov 2016 – Nov 2026)
A ₹5,000 monthly SIP for the last 10 years (Nov 2016 – Nov 2026)
Real NAV backtest
A ₹5,000 monthly SIP would be worth ₹12,59,952 today — ₹6,00,000 invested, 14.4% XIRR.
₹6,00,000
Invested
₹12,59,952
Value today
14.4%
XIRR (p.a.)
A ₹1,00,000 lumpsum, the last 10 years (Nov 2016 – Nov 2026)
Real NAV backtest
₹1,00,000 invested 10 years ago would be ₹3,72,305 today (14.1% CAGR).
A regular withdrawal plan (SWP)
Real NAV backtest
A ₹10,00,000 corpus withdrawing ₹5,000/month since Nov 2016 would still hold ₹24,63,098.
Fund vs Benchmark (TRI)
Same SIP, benchmark total-return index
The same SIP would be worth ₹12,59,952 in this fund vs ₹15,30,132 in the benchmark — underperformance of ₹2,70,180.
Buying the worst day
Real NAV backtest
₹1,00,000 invested on the worst market day of the last 10 years (Nov 2016 – Nov 2026) (22 Mar 2020) would be ₹4,43,615 today (4.44×).
Historical simulation using actual published NAVs for the stated period. Past performance may or may not be sustained in the future. Not investment advice.
Risk Metrics
Trailing 1 year, annualised-0.08
Sharpe Ratio
—
Alpha
—
Beta
-0.07
Sortino
14.22%
Std Dev
-14.10%
Max Drawdown
Performance Comparison
Sectoral allocation
as of 30 Sept 2026- Pharmaceuticals & Biotechnology9.60%
- Banks8.54%
- Industrial Products7.01%
- Retailing6.50%
- Finance6.21%
- Consumer Durables6.15%
- Electrical Equipment5.56%
- Auto Components5.50%
- IT - Software5.34%
- Capital Markets4.55%
- Realty3.08%
- Chemicals & Petrochemicals2.99%
Each sector links to the mutual funds most exposed to it.
Related reading
Thinking about UTI Mid Cap Fund · Regular · Growth?
Talk to our AMFI-registered team — free, no pressure. We'll help you see if this fund fits your goals.
Fund Details
Available transactions
Portfolio holdings
- 1Coforge Ltd3.01%
- 2Au Small Finance Bank Ltd2.75%
- 3Blue Star Limited2.55%
- 4Aurobindo Pharma Ltd.2.24%
- 5Ajanta Pharma Ltd.2.15%
- 6Apl Apollo Tubes Ltd2.11%
- 7Federal Bank Ltd.1.98%
- 8Phoenix Mills Ltd1.95%
- 9Info-Edge (India) Ltd.1.92%
- 10Shriram Finance Ltd1.92%
What this fund does
UTI Mid Cap Fund · Regular · Growth seeks to generate long-term capital appreciation by investing in mid-cap companies — ranked 101st to 250th by market capitalisation. These companies offer a balance of growth potential and relative stability, with wider price swings than large-caps.
About This Fund
UTI Mid Cap Fund · Regular · Growth is a Mid Cap mutual fund offered by UTI Mutual Fund. The fund has been operational for over 22 years. It manages assets worth ₹12,421 Cr, reflecting investor confidence in the fund's strategy. It benchmarks its performance against Nifty Midcap 150 TRI. The current expense ratio is 1.97%.
Who Should Invest?
- •Aggressive investors comfortable with significant short-term volatility
- •Investors with a long-term horizon of 7+ years who can ride out market cycles
- •SIP investors who can benefit from rupee cost averaging during market fluctuations